SkinBioTherapeutics
plc
("SkinBioTherapeutics" or "the Group")
Notice of Full Year results
and Investor Meet Company presentation
29
November 2024 - SkinBioTherapeutics
plc (AIM: SBTX), a
life science company focused on skin health, announces that the
Group's full year results for the year to 30 June 2024 will be
released on Wednesday 4 December 2024.
The results will be available via
the London Stock Exchange's Regulatory News Service (RNS) and on
the Investor Relations section of the Group's website
HERE.
Stuart Ashman, CEO and Manprit
Randhawa, CFO will provide a live presentation via the Investor
Meet Company platform at 10.00am GMT on Tuesday 10 December
2024.
The presentation is open to all
existing and potential SkinBioTherapeutics shareholders. Questions
can be submitted pre-event via the
Investor Meet Company dashboard up until 9 December 2024, 09.00am GMT, or at any time during
the live presentation.
Investors can sign up to Investor
Meet Company for free via this link. Investors who already
follow SkinBioTherapeutics plc on the Investor Meet Company
platform will automatically be invited.
-Ends-
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
+44 (0) 191 495
7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
+44 (0) 20 7220
0500
|
|
Vigo
Consulting (financial press)
Rozi Morris
|
+44 (0) 20 7390
0230
SkinBio@vigoconsulting.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Group's proprietary
platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the
University of Manchester.
The Group's foundation business is
targeting the skin healthcare market via five pillars, the most
advanced of which are cosmetic skincare (SkinBiotix) and food
supplements to modulate the immune system by harnessing the
gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership
with Croda plc and the Group's first in-house product,
AxisBiotix-Ps™, is a food supplement to address the symptoms of
mild to moderate psoriasis.
The Group is also acting as a
consolidator and is making acquisitions in complementary areas such
as skin care and cosmetic applications, that also bring new
distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar
products.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com.